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Summary. S100P - low molecular weight acidic protein
has been shown to be involved in processes of
proliferation, survival, angiogenesis, multidrug
resistance and metastasis in various human
malignancies. In breast cancer, S100P expression is
associated with immortalization of neoplastic cells and
aggressive tumour behaviour, indicating that this protein
may have adverse prognostic value. We analyzed nuclear
and cytoplasmic expression of S100P in 85 stage II
breast cancer patients with a median follow up of 17
years. Immunohistochemical reactions were performed
on paraffin sections of primary tumours, using
monoclonal antibodies against S100P. We also studied
prognostic value of S100P mRNA expression using the
KM plotter which assessed the effect of 22,277 genes on
survival in 2422 breast cancer patients. Moreover, the
relationship was examined between expression of S100P
in cells of four breast cancer cell lines and their
sensitivity to the 11 most frequently applied cytotoxic
drugs. Univariate and multivariate analyses showed that
higher expression of nuclear S100P (S100Pn) was
typical for cases of a shorter overall survival and
disease-free time. KM plotter analysis showed that
elevated S100P expression was specific for cases of a
relapse-free survival and distant metastases-free
survival. No relationship could be documented between
expression of S100P and sensitivity of breast cancer
cells to cytostatic drugs. We demonstrated that a high
S100Pn expression level was associated with poor
survival in early stage breast cancer patients. Since
preliminary data indicated that expression of S100P was
up-regulated by activation of glucocorticoid receptor and
several agents manifested potential to activate or inhibit
S100P promoter activity, this protein might become a
therapy target and warrants further studies with respect
to its prognostic, predictive and potentially therapeutic
value. 
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Introduction
Breast cancer is the most common malignancy
among women in the developed countries, with a general
upward trend in incidence (Ferlay et al., 2004). The
majority of patients are diagnosed with early stage breast
cancer and are treated with radical intent. Adjuvant
treatment is commonly used to reduce the risk of relapse
and death. Results of prospective randomized trials
confirmed the absolute reduction of breast cancer
mortality in chemotherapy-treated patients by 10% and
3% and the risk of relapse by 12% and 4% in
premenopausal and postmenopausal women,
respectively. Endocrine treatment in patients with
estrogen receptor (ER)-positive tumours reduced the risk
of death and relapse by 31% and 39%, respectively
(Early Breast Cancer Trialists’ Collaborative Group,
2005). One year of adjuvant trastuzumab in HER-2
positive subgroup added a supplementary benefit (Perez
et al., 2007). However, taking into account the real risk
of recurrence, in the current practice the majority of
patients with early breast cancer receive adjuvant
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treatment needlessly, either because they are cured with
surgery alone or due to the lack of reliable predictive
factors so they receive ineffective treatment and suffer
from a relapse in spite of it. Therefore, an appropriate
patient selection to adjuvant treatment becomes crucial.
According to current recommendations, indication for
adjuvant therapy and choice of particular treatment
modalities are based on the likelihood of response to
specific therapies and magnitude of the risk of
recurrence (Goldhirsch et al., 2009).
Prognosis of newly diagnosed breast cancer
predominantly relies on stage, a few clinical factors,
pathologic features of the tumour and status of hormonal
and HER-2 receptors. However, breast cancer is a
heterogenous disease, and even tumours sharing
identical histological characteristics have a variable
prognosis and may manifest also a variable response to
therapy. Molecular features of malignant tumours are
currently being comprehensively investigated. Both
prognostic and predictive biomarkers are essential to
individualize clinical management of the disease. 
S100P is a low molecular weight acidic protein,
which belongs to the EF-hand superfamily of calcium
binding proteins. It was originally isolated from human
placenta, and its presence was detected in various
normal and malignant cells. S100P can be detected in the
cytoplasm and/or cell nucleus and it is up-regulated in
various human malignant tumours, such as pancreatic,
lung, prostate, colorectal, ovarian and breast cancer
(Guerreiro Da Silva et al., 2000; Mousses et al., 2002;
Logsdon et al., 2003; Diederichs et al., 2004; Wang et
al., 2006; Fuentes et al., 2007). Several experimental
studies showed that S100P, involved in processes of
proliferation, survival, angiogenesis and metastasis, may
contribute to development of a malignant phenotype
(Arumugam et al., 2005; Wang et al., 2006; Surowiak et
al., 2007; Parkkila et al., 2008). The S100P mechanism
of action is not fully known. It was shown that S100P
exerted both intracellular and extracellular functions
(Arumugam et al., 2005). Different signalling pathways
are involved in S100P transcriptional regulation,
activated by hormones (glucocorticoids) and growth
factors such as EGF (epidermal growth factor) and BMP
(bone morphogenic factor). S100P is secreted to
extracellular space where it binds to RAGE (receptor for
advanced glycation end-product) and it seems to
function as a signalling molecule (Donato, 2003;
Arumugam et al., 2004). Although it may be a biomarker
of chemotherapy and endocrine therapy resistance,
results of studies are contradictory. In our previous
studies, performed on 30 cell lines, we compared gene
expression profiles obtained using the Affymetrix
U133A arrays with profiles of resistance to 11 cytostatic
drugs applied in clinically relevant concentrations. In the
study we demonstrated that augmented expression of
S100P protein characterized cells resistant to
cyclophosphamide, etoposide, methothrexate and
mitoxantron (Györffy et al.,2006). In another study we
have shown that elevated expression of S100P is an
unfavourable prognostic factor in ovarian cancer patients
(Surowiak et al., 2007).
In breast tumours S100P expression is seen
specifically on cancer cells, therefore it appears to be an
indicator of malignancy (Guerreiro Da Silva et al.,
2000). It has been shown that S100P overexpression is
associated with poor prognosis (Wang et al., 2006).
In the present study, we tested the prognostic value
of S100P for formalin-fixed paraffin-embedded (FFPE)
tissue obtained from 85 patients with stage II primary
ductal breast carcinoma with a median follow up of 17
years. 
Material and methods
Patients
Consecutive breast cancer patients (n=85) diagnosed
with clinical stage II ductal breast cancer (stage pT1-3,
pN0-1) treated in Lower Silesia Oncology Centre from
January 1992 to June 1993 were identified. Patient
characteristics are listed in Table 1. All patients treated
with adjuvant chemotherapy received CMF regimen
(cyclophosphamide, 5-fluorouracyl, methotrexate) for 6
cycles. Women with hormonally responsive disease
received tamoxifen for 5 years. Median follow up time
was 17 years for the whole group. Pathologic data were
obtained from standard pathology reports from a local
laboratory. Hormonal receptor status was examined by
immunohistochemistry (IHC) and assessed using Allred
score. HER-2 status was also assessed by IHC and
scored by classical 0-3 score.
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Table 1. Patient and tumour characteristics.
Characteristics Number of patients (%)
All patients 85 (100)
Age (mean)
<50 25 (29.4)
≥50 60 (70.6)
Grade
1
2 61 (71.8)
3 24 (28.2)
Lymph node metastases
Yes 36 (42.3)
No 49 (57.7)
ER 
ER negative (0-9 %) 30 (35.3)
ER positive (>10%) 55 (64.7)
PgR
PgR negative (0-9%) 35 (41.2)
PgR positive (>10%) 50 (58.2)
HER-2
HER-2 negative (IHC 0, 1, 2) 66 (77.6)
HER-2 positive (IHC 3) 19 (22.4)
Adjuvant chemotherapy (alone) 21 (24.7)
Adjuvant hormonal therapy (alone) 46 (54.1)
Adjuvant chemoendocrine therapy 3 (3.6)
No adjuvant systemic treatment 15 (17.6)
Immunohistochemistry
Formalin-fixed, paraffin embedded tissue was
freshly cut (4 µm). The sections were mounted on
Superfrost slides (Menzel Gläser, Germany), dewaxed
wtih xylene, and gradually hydrated. Activity of
endogenous peroxidase was blocked by 5 min exposure
to 3% H2O2. All the studied sections were boiled for 15
min at 250W in the Antigen Retrieval Solution
(DakoCytomation, Denmark). Then, immunohisto-
chemical reactions were performed using the mouse
monoclonal antibodies detecting S100P (BD Biosciences
Pharmingen, Franklin Lakes, NJ, USA) at dilution 1:250
in Antibody Diluent, Background Reducing
(DakoCytomation, Denmark), ER (monoclonal, clone
1D; dillution 1:100; Dako), PR (monoclonal clone 636;
dillution 1:100 x; Dako), HER-2 (HercepTest, based on
the Dako A0485 polyclonal antibody, and the CB11
monoclonal antibody dillution 1:100; Dako). Tested
sections were incubated with antibodies for 1 h at room
temperature. Subsequent incubations involved
biotinylated antibodies (15 min, room temperature) and
streptavidin-biotinylated peroxidase complex (15 min,
room temperature) (LSAB+, HRP, DakoCytomation,
Denmark). DAB (DakoCytomation, Denmark) was used
as a chromogen (7 min, at room temperature). All the
sections were counterstained with Meyer’s hematoxylin
(DakoCytomation, Denmark). In every case, control
reactions were included, in which the specific antibody
was substituted by the Primary Mouse Negative Control
(DakoCytomation, Denmark) (Surowiak et al., 2007).
Control reactions
Control reactions for S100P were also performed on
paraffin sections from six healthy human placentas and
on paraffin sections from ten healthy human breast
tissues (from the archive of the Department of Histology
and Embryology, University School of Medicine,
Wrocław, Poland) (Surowiak et al., 2007).
Cell lines and cell culture
In our study, we used 4 human breast cancer cell
lines: MCF-7, CAMA-1, SK-BR-3 and R-103. The cells
were cultured in Leibovitz L-15 medium (Bio Whittaker,
Walkersville, MD, USA) supplemented by 10% foetal
calf serum (Gibco BRL, Grand Island NY, USA), 1 mM
L-glutamine, 80 IE/l insulin, 2.5 mg/l transferrin, 1 g/l
glucose, 1.1 g/l NaHCO3, 1% minimal essential vitamins
and 20,000 kIE/l trasylol in a humified atmosphere in
5% CO2 at 37°C. Prior to resistance testing,
Mycoplasma tests were performed using the Venor Mp
kit, according to the manufacturer ’s instructions
(Minerva Biolabs GmbH, Berlin, Germany).
Resistance tests
Drugs were used in their commercially available
form (except cyclophosphamide, which was used in its
activated form). Each drug was applied to the cells in 3
concentrations (C1, C2, C3). C1=10-1 x C2 and C3=10 x
C2. Concentration C2 was deduced from levels assessed
to be clinically achievable in tumour tissue, as discussed
previously (Györffy et al., 2006) (Table 2). In each
experiment, 500 cells/microtiter dish were seeded onto
96-well plates. After 2 days, precontrol cells were fixed
and stained using sulforhodamine B (SRB). At the same
time, triplicate cultures were prepared with all 11 studied
drugs at C1, C2 and C3 concentrations. After 4 days,
incubation was terminated by replacing the medium with
10% trichloroacetic acid, followed by incubation at 4°C
for 1 hr. Subsequently, the plates were washed 5 times
with water and stained by adding 100 µl 0.4% SRB
(Sigma, St. Louis, MO, USA) in 1% acetic acid for 10
min at room temperature. Washing the plates 5 times
with 1% acetic acid eliminated unbound dye. After air-
drying and resolubilization of the protein-bound dye in
10 mM Tris-HCl (pH 8.0), absorbance was read at 562
nm in an Elisa-Reader (EL 340 Microplate Bio Kinetics
Reader, BIO-TEK Instruments, Winooski, VT, USA).
The measurements were performed in triplicate in 3
independent experiments. For the calculation of the RI
values, the averages of all 9 measurements were used. 
The resistance index (RI) was estimated by the
formula:
RI = (npost/npre) x [(n2-npre) / (npost-npre) x 100]
where npre is the medium absorbance value of precontrol
at the C2 concentration, npost is the medium absorbance
value of control and n2 is the medium absorbance value
of stained cells tested with the chosen concentration of
the studied drug.
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Table 2. Drugs used to establish resistance patterns and their C2
concentrations (the clinically available drug in the tumour).
Drug C2 (µM/ml) Supplying company
5-Fluorouracil 38.43 x 10-5 Gry-Pharma
Cisplatin 16.66 x 10-5 Gry-Pharma
Cyclophospha-mide (hydroxylated) 50.16 x 10-5 Asta Werke
Doxorubicin 0.86 x 10-5 Cell-Pharma
Etoposide 2.37 x 10-5 Gry-Pharma
Methotrexate 0.3 x 10-5 Wyeth-Lederle
Mitomycin C 1.49 x 10-5 Hexal
Mitoxantrone 0.38 x 10-5 Wyeth-Lederle
Paclitaxel 0.29 x 10-5 Bristol
Topotecan x 10-5 Glaxo Smith Kline
Vinblastin 0.1 x 10-5 Gry-Pharma
Table 3. Evaluation criteria of ABCC2 expression using IRS
(ImmunoReactive Score) score.
Percentage of positive cells Points Intensity of reaction Points
No positive cells 0 No reaction 0
<10% positive cells 1 Weak reaction 1
10-50% positive cells 2 Moderate reaction 2
51-80% positive cells 3 Intense reaction 3
>80% positive cells 4
Immunocytochemistry
Immunostaining of S100P was performed using the
studied panel of breast cancer cell lines. Cells were
grown on microscopic slides and fixed in ice-cold
methanol-acetone mixture (1:1) for 10 minutes.
Immunostaining reaction was performed in triplicate as
described above.
Evaluation of reaction intensity
Intensity of immunohistochemical reactions was
estimated independently by two pathologists. In doubtful
cases a re-evaluation was performed using a double-
headed microscope and staining was discussed until a
consensus was achieved. In order to evaluate the S100P
expression, a semi-quantitative scale of ImmunoReactive
Score (IRS) was applied, which took into account
intensity of the colour reaction (0: no reaction, 1: weak
reaction, 2: moderate intensity, 3: intense reaction) as
well as proportion of positive cells (0: no positive cells,
1: <10% positive cells, 2: 10-50% positive cells, 3: 51-
80% positive cells, 4: >80% positive cells). The final
score represented the product of points given for
individual characters and ranged between 0 and 12
(Table 3). Evaluation of estrogen and progesterone
receptor expression was performed using standard
methods. The staining intensity (0-3 scale) and
proportion of positive cells (0-5 scale) were reported and
the Allred score (AS) that combines the two was
calculated. HER-2 status was evaluated using the FDA-
approved scoring system of 0, 1+, 2+, and 3+ (0: no
immunostaining, 1+: weak immunostaining, less than
30% of tumour cells; 2+: complete membranous
staining, either uniform or weak in at least 10% of cells;
3+: uniform intense membranous staining in at least 30%
of cells).
Statistical analysis
All statistical analyses were conducted using
Statistica 8.0 PL software (Statsoft, Poland). Disease-
free survival (DFS) was defined as the time between the
primary surgical treatment and date of relapse or death,
whichever occurred first, and DFS was censored at last
follow up for those who were alive without recurrence.
Overall survival (OS) was defined as the time between
the primary surgical treatment and death from any cause,
whichever occurred first, and OS was censored at last
follow up for those who were alive. 
Clinicopathologic variables considered in univariate
analysis were: age at the time of primary surgery, which
was a surrogate for the date of diagnosis (continuous
variable), lymph node status (positive vs negative),
hormonal receptor (HR) status (by IHC; positive vs
negative), and HER-2 status (by IHC; positive [+3] v
negative [0, 1 or 2]). Although according to current
standards all tumours exhibiting any expression of HR
are considered endocrine responsive, for the purpose of
this analysis we excluded tumours with low ER/PR level
from HR- positive group and considered as a HR-
positive only tumours with ≥10% stained malignant
cells. Correlations between these factors and S100P were
analysed using Chi2 tests. 
In order to estimate survival we used Kaplan Meier
statistics, log rank tests, test F of Cox and Cox
proportional hazard regression.
KM plotter online survival analysis
The KM plotter was capable of assessing the effect
of 22,277 genes on survival in 2422 breast cancer
patients (Gyorffy et al., 2010). A background database
was established using gene expression data and survival
information on 2422 patients downloaded from GEO
(Affymetrix HGU133A and HGU133+2 microarrays).
The median relapse-free survival was 6.43 years. After
quality control and normalization only probes present on
both Affymetrix platforms were retained (n=22,277).
The background database was handled by a MySQL
server, which integrates gene expression and clinical
data simultaneously. In order to analyze the prognostic
value of a particular gene, the samples were split into
two groups according to the median (or upper / lower
quartile) expression of the gene. The two groups could
be compared in terms of relapse free survival, overall
survival and distant metastasis free survival.
Results
Immunohistochemical staining of breast cancer for
S100P
The immunohistochemical staining for S100P was
predominantly nuclear (S100Pn). Of the 85 specimens
evaluated, 23 (27.0%) showed no reaction. Sixty two
specimens (73.0%) showed nuclear expression of S100P,
35 (41.2%) manifested borderline or weak expression
(IRS: 1-4) and 27 of them (31.8%) showed strong
expression (IRS: 6-12). For the purpose of analysis,
patients with S100Pn negative tumours (IRS:0) and
cancers with low expression (IRS:1-4) were combined.
Fifty eight tumours exhibited lack of expression or low
nuclear expression of S100Pn, 27 (31.8%) manifested
high expression (IRS: 6-12). Cytoplasmic expression of
S100P (S100Pc) was seen in 59 (69.4%) of tumours, and
the majority (61.2%) of samples were S100Pc negative
or exhibited borderline or weak expression (n=52,
61.2%) (Fig. 1). 
S100P expression and clinicopathologic data
The relationships between S100P expression and the
clinicopathological data of studied patients was assessed
using Chi2 test. No correlation was seen between S100P
expression and the assessed clinicopathologic
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parameters (Table 4).
S100P expression versus overall survival (OS) and
disease free survival (DFS) of the studied patients
In the Kaplan Meier analysis, OS and DFS were
compared between groups with lower or negative S100p
expression (IRS: 0 to 4 for S100Pn and 0 to 2 for
S100Pc), and higher S100p expression (IRS: 6 to12 for
S100Pn and 3 to12 for S100Pc). Patients with strong
S100Pn expression had significantly shorter OS
(P<0.00001) (Fig. 2) and DFS (P = 0.00002) (Fig. 3).
S100Pc expression exerted no impact on survival (Figs.
4, 5). 
When we split the group into node-negative (N/-/)
and node-positive (N/+/) cases, association between
S100Pn and OS remained significant in both N/+/ and
N/-/ subgroups (for N/+/ and N/-/ P=0.00002 and
P=0.04105, respectively). However, high S100Pn was
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Fig. 1. Immunohistochemical localization of S100P expression in breast
cancer: A. Cytoplasmic reaction; brown reaction product; S100Pn
IRS=0, S100Pc IRS=8 (hematoxylin). B. cytoplasmic and nuclear
reaction; brown reaction product; S100Pn IRS=9, S100Pc IRS=8
(hematoxylin). C. nuclear reaction; brown reaction product; S100Pn
IRS=9, S100Pc IRS=2 (hematoxylin). A, B, x 400; C, x 200
Fig. 2. Kaplan-Meier curves for survival and expression of S100P in the
studied group of breast cancer patients: nuclear S100P (S100Pn)
expression and overall survival time (log-rank P<0.00001; Cox F test
P=0.00159; regression of Cox proportional hazard P=0.00233).
Table 4. Correlation between S100P expression and various
clinicopathologic parameters (Chi2 test).
Characteristics S100 Pn P value S100Pc P value
Histologic grade 0.47621 0.40553
Lymph node metastases 0.22656 0.66007
ER (>10%) 0.27316 0.47341
PgR (>10%) 0.85228 0.59675
HER-2 0.27190 0.73906
Age (>50) 0.73025 0.63035
S100Pn: S100P nuclear staining; S100Pc: S100P cytoplasmic staining;
ER: estrogen receptor, PgR: progesterone receptor
associated with a significantly worse DFS only in N/+/
group (P=0.00012 ). In N/-/ patients this association was
of borderline significance (P=0.05777) . A correlation
with OS, DFS and S100Pc was found neither in N/+/,
nor in N/-/ subgroup (for N/+/ and N/-/ : P>0.05). 
Using univariate analysis, we also tested the
prognostic value of S100P in subgroups of patients
manifesting various HER-2 expression and hormonal
receptor status. The computations have shown, that
elevated S100Pn expression is specific for cases of
shorter OS and DFS in both in all studied subgroups (in
HER/-/: P=0.00001 and P=0.00003 for OS and DFS,
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Fig. 4. Kaplan-Meier curves for survival and expression of S100P in the
studied group of breast cancer patients: cytoplasmic S100P (S100Pc)
expression and overall survival time (log-rank P=0.81148; Cox F test
P=0.42430).
Fig. 3. Kaplan-Meier curves for survival and expression of S100P in the
studied group of breast cancer patients: nuclear S100P (S100Pn)
expression and disease-free survival time (log-rank P=0.00002; Cox F
test P=0.00002; regression of Cox proportional hazard P=0.00005).
Table 5. Univariate and multivariate analysis of the relationships between various clinicopathologic parameters, nuclear S100P expression (S100Pn),
cytoplasmic S100P expression (S100Pc) and the overall survival time of all the studied patients. The multivariate analysis was performed only for the
factors significantly related to survival time in univariate analysis.
Univariate analysis Multivariate analysis
Studied parameter % Censored CPS (range 0-1) 0-n 1-n Cox F test P value Hazard ratio 95% CI Regression of Cox proportionalhazard P value
pN
26,5% 0-49
0.00159 3.25 1.62-6.52 0.00233
58,3% 1-36
pT
18,8% <2cm-16
0.06388 -
52,5% >2cm-59
Grade 37,7% G2-61 0.28180 -
45,8% G3-24
Menopausal status
25,9% Pre 27
0.03099 2.07 0.90-4.76 0.06834
46,5% Post 58
HER-2
36,4% 0-2:66
0.21392 -
52,6% 3:19
ER
36,6% NEG-30
0.21307 -
41,8% POS-55
PR
31,4% NEG-35
0.57582 -
46,0% POS-50
S100Pn 24,1% NEG-58 0.00001 5.64 2.81-11.29 0.00001
74,0% POS-27
S100Pc 40,4% NEG-52 0.42430 -
39,4% POS-33
respectively, in ER/PR/+/: P=0.00002 and P=0.00027 for
OS and DFS, respectively). 
At the subsequent stage of analysis, using the Cox F
test a relationship was examined between
clinicopathological data of the patients and expressions
of S100P on one hand and their OS and DFS on the
other. The factors significantly correlated with patients’
survival including pN, menopausal status and expression
of S100Pn (Table 5). Calculations conducted by Cox
proportional hazard regression showed that only pN and
S100Pn manifested a significant relationship with
patients’ survival (Table 5). The analysis showed pN,
menopausal status and S100Pn have relationship with
the duration of DFS (Table 6).
At the final stage of Cox proportional hazard
regression grouping variables were applied. The two
selected parameters which in the studied group exerted a
significant influence on patients’ survival included pN
and menopausal status. The analysis confirmed that
elevated expression of S100Pn was typical for patients
with abbreviated OS and DFS (Table 7). On the case of
S100Pc no significant relationship with patients’
survival could be demonstrated (Table 7). 
S100P expression and sensitivity of the breast cancer
cell lines to cytostatic drugs
The studied cell lines demonstrated the following
intensity of reaction for S100P: MCF-7: S100Pn, IRS=0;
S100Pc, IRS=9; CAMA-1: S100Pn, IRS=0; S100Pc,
IRS=1; SK-BR-3: S100Pn, IRS=0; S100Pc, IRS=0; R-
103: S100Pn, IRS=3; S100Pc, IRS=9. The results of
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Fig. 5. Kaplan-Meier curves for survival and expression of S100P in the
studied group of breast cancer patients: cytoplasmic S100P (S100Pc)
expression and disease-free survival time (log-rank P=0.67347; Cox F
test P=0.0.35074).
Table 6. Univariate and multivariate analysis of the relationships between various clinicopathologic parameters, nuclear S100P expression (S100Pn),
cytoplasmic S100P expression (S100Pc) and the disease-free time of all the studied patients. The multivariate analysis was performed only for the
factors significantly related to disease-free time in univariate analysis.
Univariate analysis Multivariate analysis
Studied parame-ter % Censored CPS (range 0-1) 0-n 1-n Test F Coxa P value Hazard ratio 95% CI Regression of Cox proportionalhazard P value
pN
34,7% 0-49
0.00587 2.65 1.40-5.01 0.00932
61,1% 1-36
pT
25,0% <2cm-16
0.09534 -
59,3% >2cm-59
Grade
42,6% G2-61
0.21185 -
54,2% G3-24
Menopausal status
29,6% Pre 27
0.02144 2.13 1.07-4.63 0.04813
53,4% Post 58
HER-2
42,4% 0-2:66
0.17759 -
57,9% 3:19
ER
43,3% NEG-30
0.25118 -
47,2% POS-55
PR
45,7% NEG-35
0.36428 -
46,0% POS-50
S100Pn
36,2% NEG-58
0.00002 4.55 2.39-8.67 0.00005
66,7% POS-27
S100Pc
28,8% NEG-52
0.35074 -
72,7% POS-33
conducted cytotoxicity tests and the results of
immunocytochemical reactions are depicted in Figs. 6, 7.
The investigations demonstrated no relationship between
expression of S100P in breast cancer cells and sensitivity
of the cells to cytostatic drugs.
KM Plotter online survival analysis
Using KM Plotter online survival analysis of the
prognostic value of S100P mRNA (Affy id.: 204351_at)
an elevated mRNA of S100P expression was shown to
have a negative impact on patient’s relapse-free and
distant metastases-free survival in the entire group, and
of relapse-free time in the subgroups of estrogen
receptor positive patients and lymph node negative
patients (Table 8).
Discussion
Treatment tailored to specific characteristics of a
patient and a tumour may improve patients outcome. It
can also alter management strategies. An understanding
of cancer biology is crucial and should be translated into
development of tests to identify prognostic and
predictive molecular markers. It is hoped that molecular
diagnostics will be more precise and reliable that
currently known and commonly used clinicopathologic
factors. 
In the treatment of breast cancer prognostic factors it
is necessary to determine prognosis and to identify
women at high risk of recurrence, who may potentially
benefit from adjuvant treatment. On the other hand, the
ability to characterize patients who are cured with
surgery alone or are candidates for less invasive therapy
would spare avoidable adverse effects and a substantial
cost of treatment. Indications for endocrine and anti-
HER-2 treatment based on molecular predictors are
clear. In the absence of predictive factors, indicators for
chemotherapy are less certain. Additionally, the
currently available prognostic factors fail to accurately
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Fig. 6. Immunocytochemical location of S100P expression in cells of: MCF-7 breast cancer cell line (A), CAMA-1 breast cancer cell line (B), SK-BR-3
breast cancer cell line (C) and R-103 breast cancer cell line (D).
determine the risk of recurrence or to select candidates
for adjuvant chemotherapy. The vast majority of women
with breast cancer are treated to provide a benefit to few
of the patients. A number of biomarkers are being
investigated in recent years with a hope to provide
prediction of outcome. So far, only a few (HER-2 status,
expression of hormonal receptors, urokinase
plasminogen activator and plasminogen activator
inhibitor 1 [UPA/PAI-1], proliferation assessed by Ki67-
labelling index and multigene assay) are recommended
for routine practice. Clinical utility of other biomarkers,
such as DNA/ploidy by flow cytometry, p53, cathepsin
D, cyclin E, is limited due to insufficient evidence
(Goldhirsch et al., 2009).
Features indicating metastatic potential and
biological aggressiveness of the tumour might indicate
the need for adjuvant chemotherapy. 
Several in vitro and in vivo studies indicate that
S100P is a measure of invasiveness and aggressive
tumour behaviour in various tumour types, such as
prostate, pancreatic, colorectal, lung and breast cancer
(Guerreiro Da Silva et al., 2000; Mousses et al., 2002;
Logsdon et al., 2003; Diederichs et al., 2004; Wang et
al., 2006; Fuentes et al., 2007). As we previously
described, high S100 P score is also an adverse
prognostic factor in ovarian cancer (Surowiak et al.,
2007). S100P seems to be a reliable indicator of
malignant evolution. Not expressed in normal breast
tissue, S100P can be detected in hyperplasia, which is a
lesion at high risk of malignancy in the forms of an
invasive or in situ carcinoma (Guerreiro Da Silva et al.,
2000). In the recently published analysis of suppression
subtracted hybridization libraries genes associated with
breast cancer progression, S100 P was associated with
aneuploidy in cell lines and relapse/death in patients
(Barraclough et al., 2010). The prognostic value of
S100P in breast cancer patients was examined in a
retrospective analysis performed by Wang et al. in a
series of 303 primary breast cancers (Wang et al., 2006). 
In agreement with our findings they showed strong
association with reduced survival in S100P positive
tumours. They also found a correlation between high
S100P and lymph node involvement. As our study was
performed in a uniform stage II group, we were able to
prove that S100P was an indicator of poor prognosis,
regardless of stage. Although Wang et al. used different
criteria assessing the level of expression, the frequency
of negative, borderline positive and S100P positive
tumours in their study were similar. They identified
S100P, S100A4 and osteopontin as the most powerful
independent indicators of death in the studied group
(Wang et al., 2006). S100P was also found to be
associated with HER-2 phenotype and ER expression
(Mackay et al., 2003; Schor et al., 2006). It was
suggested that HER-2 up regulated expression of S100P
in breast tumours (Mackay et al., 2003). We failed to
confirm any correlation between S100P and hormonal
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Table 7. Multivariate analysis of the relationships between nuclear
(S100Pn) and cytoplasmic (S100Pc) expressions and the overall
survival and disease-free survival time. The analysis included effect of
grouping variables which were significantly linked to overall survival and
disease-free survival time (pN and menopausal status).
Studied Hazard 95% CI Regression of Cox 
parameter ratio proportional hazard P value
Grouping variable: pN
S100Pn
OS 6.47 3.04-13.79 <0.00001
DFS 4.65 2.35-9.20 0.00004
S100Pc
OS 1.11 0.55-2.23 0.83882
DFS 1.03 0.54-1.97 0.66280
Grouping variable: menopausal status
S100Pn
OS 5.74 2.86-11.54 0.00001
DFS 4.43 2.32 8.43 0.00006
S100Pc
OS 0.97 0.48-1.95 0.84033
DFS 0.93 0.49-1.97 0.67564
Table 8. KM Plotter analysis of prognostic significance of the S100P
mRNA expression.
Studied parameter n P value
The entire group
Overall survival 464 0.2195
Relapse-free survival 2422 <0.0001
Distant metastases-free survival 673 0.0344
Estrogen receptor positive patients
Overall survival 134 0.6669
Relapse-free survival 1499 0.0004
Distant metastases-free survival 457 0.6473
Estrogen receptor negative patients
Overall survival 64 0.734 
Relapse-free survival 442 0.9524
Distant metastases-free survival 101 0.1476
Lymph node positive patients
Overall survival 0 -*
Relapse-free survival 548 0.0833
Distant metastases-free survival 111 0.2143
Lymph node negative patients
Overall survival 198 0.3433
Relapse-free survival 1316 0.017
Distant metastases-free survival 447 0.1649
Truly prognostic datasets (patients not treated with systemic therapy)
Overall survival 609 0.3823
Relapse-free survival 609 0.0223
Distant metastases-free survival 609 0.1814
ER-positive endocrine treated datasets
Overall survival -* -
Relapse-free survival 414 0.6634
Distant metastases-free survival 414 0.3356
* Analysis not possible to perform.
receptors or HER-2. 
We found that only nuclear expression of S100P had
an impact on patients’ outcome. Lack of prognostic
value of cytoplasmic S100P expression observed in our
study is not clear. S100P is localized intracellularly in
nucleus, cytoplasm or cell membrane and it can also be
secreted extracellulary. It is likely that S100P
translocates within a cell and that it is a dynamic
process, associated with its functional status and
interactions (Guerreiro Da Silva et al., 2000; Sato et al.,
2004; Parkkila et al., 2008). Nuclear translocation seems
to be a result of interaction with S100P binding protein
(S100PBPR) (Dowen et al., 2005), whereas binding to
ezrin stimulates translocation to cell periphery
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Fig. 7. Sensitivity of the studied cells to 11
cytostatic drugs of various groups: MCF-7 breast
cancer cell line (A), CAMA-1 breast cancer cell
line (B), SK-BR-3 breast cancer cell line (C) and
R-103 breast cancer cell line (D).
(Koltzscher et al., 2003). This might explain
contradictory data obtained in various studies. 
In a few reports it was shown that S100P may also
have predictive value, although these findings are
controversial. S100P overexpression was associated with
resistance to 5-fluorouracyl in pancreatic cancer cells
and to irinotecan in prostate cancer (Arumugam et al.,
2005; Basu et al., 2008). In our previous study
performed on cell lines we found a correlation between
overexpresion of S100P and resistance to
cyclophosphamide, etoposide, methotrexate and
mitoxantrone (Györffy et al., 2006). In contrast to these
observations, studies on ovarian cancer cells exposed to
carboplatin and paclitaxel, 5-fluorouracyl, etoposide and
doxorubicin showed a possible chemosensitization effect
of S100P (Wang et al., 2008). Similarly, studies on
downregulation of S100P in colon cancer cell line 8307
have shown that S100P was associated with oxaliplatin
sensitivity in these drug resistant cells (Tang et al.,
2007). These data suggested that drug resistance/
sensitivity may be altered by S100P, but the mechanism
of chemotherapy resistance is complex and it likely
involves a variety of pathways. We found an association
between decreased survival and high S100P score,
irrespective of the adjuvant treatment. Small subgroups
and uniform therapy did not allow an analysis assessing
predictive value of S100P. However, since patients
selection to adjuvant treatment is based on prognostic
and predictive factors and biomarkers may have both a
prognostic and a predictive value, a potential of S100P
to predict benefits from certain chemotherapeutic agents
warrants further studies. 
Another, probably the most important issue which
may have potential therapeutic implications, is a
hypothesis that S100P silencing may change aggressive
tumour behaviour, and there are agents capable of
inhibiting S100P. As a factor of poor prognosis, S100P
may become an important target in breast cancer
treatment. Most studies, however, focused on the
concept that modulation of S100P may change response
to cancer treatment. The S100P mechanism of action
involves activation of RAGE receptor and, as a
consequence, stimulation of different signalling
pathways such as: nuclear factor - B (NFκB) mitogen-
activated protein (MAP) kinase, which influence
sensitivity/resistance to cytotoxic drugs (Fuentes et al.,
2007). Observations from preclinical studies confirmed a
correlation between S100P expression and presence of
glucocorticoid receptor (GR). Activation of S100P by
hydrocortisone and dexamethasone can be blocked by a
GR antagonist, mifepristone (Gibadulinova et al., 2011).
A study in an animal model showed that inhibition of
S100P and several other S100 molecules by cromolyn
prevented activation of RAGE (Arumugam et al., 2006)
and inhibited pancreatic cancer cell growth. Several
pathway-implicated agents, such as phenothiasine,
chlorpromazine and calmodulin inhibitor N-(6-
aminohexyl)-5-chloro-1-naphtalenesulfonamide, may
reverse resistance to cisplatin (Dairkee et al., 2009). The
concept of restoration of sensitivity to a certain cytotoxic
agent by blocking S100P upregulation is certainly an
interesting field to explore. Since transcriptional
regulation of S100 P is complex and not fully
understood, involving a variety of signalling pathways,
depending on tumour type and other factors, these
observations are very promising but demand
confirmation in clinical studies. 
In our investigations, both at the level of mRNA and
at the level of protein S100P has been shown to be an
unfavourable prognostic factor in breast cancer. In
studies on the relationship between S100P expression in
breast cancer cell lines and sensitivity of the cells to
cytostatic drugs we have failed to demonstrate a
relationship between expression of S100P and
manifestation of resistance to the most popular cytostatic
drugs. It should be concluded that in cases of breast
cancer an elevated S100P expression is linked to a more
aggressive tumour biology but not to its resistance to
chemotherapy.
In conclusion, S100P expression provides important
prognostic information in early breast cancer patients. It
may be appropriate to validate the usefulness of S100P
as a predictive marker. There is growing evidence that
S100P inhibition by molecularly targeted agents may
reverse unfavourable cancer cell phenotype, which in
consequence improves patients outcome. If evidence
from experiments indicating that modulation of S100P
reverses drug resistance is confirmed in clinical studies,
S100P would become a target allowing to overcome
resistance to chemotherapy. So far, observations from
studies performed on cell lines promote hypotheses.
Information from studies on the role of S100P in breast
cancer may be useful in clarifying clinical significance
of this family of proteins and in developing novel
strategies in the treatment of breast cancer.
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